Integra LifeSciences Holdings Corporation (IART): Price and Financial Metrics
Integra LifeSciences Holdings Corporation (IART)
Today's Latest Price: $55.62 USD
Updated Nov 27 1:00pm
Add IART to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 143 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
IART Stock Summary
- IART's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 259.28 -- higher than 87.91% of US-listed equities with positive expected earnings growth.
- With a price/earnings ratio of 83.01, Integra Lifesciences Holdings Corp P/E ratio is greater than that of about 89.6% of stocks in our set with positive earnings.
- In terms of volatility of its share price, IART is more volatile than merely 6.36% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Integra Lifesciences Holdings Corp are CW, MTSC, HRC, CMCO, and PNR.
- Visit IART's SEC page to see the company's official filings. To visit the company's web site, go to www.integralife.com.
IART Stock Price Chart Interactive Chart >
IART Price/Volume Stats
| Current price | $55.62 | 52-week high | $63.23 |
| Prev. close | $54.40 | 52-week low | $34.21 |
| Day low | $54.44 | Volume | 74,400 |
| Day high | $55.62 | Avg. volume | 561,252 |
| 50-day MA | $49.50 | Dividend yield | N/A |
| 200-day MA | $48.67 | Market Cap | 4.69B |
Integra LifeSciences Holdings Corporation (IART) Company Bio
Integra LifeSciences develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in five segments: U.S. Neuro-surgery; U.S. Extremities; U.S. Instruments; U.S. Spine and Other; and International. The company was founded in 1989 and is based in Plainsboro, New Jersey.
IART Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $55.62 | $56.1 | 3% |
We started the process of determining a valid price forecast for Integra Lifesciences Holdings Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Integra Lifesciences Holdings Corp ranked in the 48th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 3.5%. As for the metrics that stood out in our discounted cash flow analysis of Integra Lifesciences Holdings Corp, consider:
- Its compound free cash flow growth rate, as measured over the past 5.67 years, is 0.3% -- higher than 67.87% of stocks in our DCF forecasting set.
- Integra Lifesciences Holdings Corp's effective tax rate, as measured by taxes paid relative to net income, is at 14 -- greater than 54.67% of US stocks with positive free cash flow.
- Relative to other stocks in its sector (Healthcare), Integra Lifesciences Holdings Corp has a reliance on debt greater than 70.06% of them.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 1% |
| 1% | 2% |
| 2% | 3% |
| 3% | 4% |
| 4% | 5% |
| 5% | 6% |
Want more companies with a valuation profile/forecast similar to that of Integra Lifesciences Holdings Corp? See PAHC, FONR, LNTH, LCI, and INBP.
Loading social stream, please wait...